Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
RS BioTherapeutics
Location
157 Baltimore St. Suite 140
Cumberland, Maryland, United States
About
The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment RS BioTherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Cumberland